These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34596681)

  • 1. The novel potent GSK3 inhibitor AF3581 reverts fragile X syndrome phenotype.
    Porceddu PF; Ciampoli M; Romeo E; Garrone B; Durando L; Milanese C; Di Giorgio FP; Reggiani A
    Hum Mol Genet; 2022 Mar; 31(6):839-849. PubMed ID: 34596681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome.
    Yuskaitis CJ; Mines MA; King MK; Sweatt JD; Miller CA; Jope RS
    Biochem Pharmacol; 2010 Feb; 79(4):632-46. PubMed ID: 19799873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence of reactive astrocytes but not peripheral immune system activation in a mouse model of Fragile X syndrome.
    Yuskaitis CJ; Beurel E; Jope RS
    Biochim Biophys Acta; 2010 Nov; 1802(11):1006-12. PubMed ID: 20600866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism.
    Mines MA; Yuskaitis CJ; King MK; Beurel E; Jope RS
    PLoS One; 2010 Mar; 5(3):e9706. PubMed ID: 20300527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice.
    Franklin AV; King MK; Palomo V; Martinez A; McMahon LL; Jope RS
    Biol Psychiatry; 2014 Feb; 75(3):198-206. PubMed ID: 24041505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
    Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
    Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential.
    Min WW; Yuskaitis CJ; Yan Q; Sikorski C; Chen S; Jope RS; Bauchwitz RP
    Neuropharmacology; 2009 Feb; 56(2):463-72. PubMed ID: 18952114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome.
    McCamphill PK; Stoppel LJ; Senter RK; Lewis MC; Heynen AJ; Stoppel DC; Sridhar V; Collins KA; Shi X; Pan JQ; Madison J; Cottrell JR; Huber KM; Scolnick EM; Holson EB; Wagner FF; Bear MF
    Sci Transl Med; 2020 May; 12(544):. PubMed ID: 32434848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperacusis in the Adult
    Ferraguto C; Bouleau Y; Peineau T; Dulon D; Pietropaolo S
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards Kinase Inhibitor Therapies for Fragile X Syndrome: Tweaking Twists in the Autism Spectrum Kinase Signaling Network.
    D'Incal C; Broos J; Torfs T; Kooy RF; Vanden Berghe W
    Cells; 2022 Apr; 11(8):. PubMed ID: 35456004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic reduction of MMP-9 in the Fmr1 KO mouse partially rescues prepulse inhibition of acoustic startle response.
    Kokash J; Alderson EM; Reinhard SM; Crawford CA; Binder DK; Ethell IM; Razak KA
    Brain Res; 2019 Sep; 1719():24-29. PubMed ID: 31128097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile X mice.
    Michalon A; Bruns A; Risterucci C; Honer M; Ballard TM; Ozmen L; Jaeschke G; Wettstein JG; von Kienlin M; Künnecke B; Lindemann L
    Biol Psychiatry; 2014 Feb; 75(3):189-97. PubMed ID: 23910948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ICAM5 as a Novel Target for Treating Cognitive Impairment in Fragile X Syndrome.
    Pei YP; Wang YY; Liu D; Lei HY; Yang ZH; Zhang ZW; Han M; Cheng K; Chen YS; Li JQ; Cheng GR; Xu L; Wu QM; McClintock SM; Yang Y; Zhang Y; Zeng Y
    J Neurosci; 2020 Feb; 40(6):1355-1365. PubMed ID: 31882402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral effects of chronic stress in the Fmr1 mouse model for fragile X syndrome.
    Lemaire-Mayo V; Subashi E; Henkous N; Beracochea D; Pietropaolo S
    Behav Brain Res; 2017 Mar; 320():128-135. PubMed ID: 27939692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated ERK/p90 ribosomal S6 kinase activity underlies audiogenic seizure susceptibility in fragile X mice.
    Sawicka K; Pyronneau A; Chao M; Bennett MV; Zukin RS
    Proc Natl Acad Sci U S A; 2016 Oct; 113(41):E6290-E6297. PubMed ID: 27663742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome.
    Gross C; Nakamoto M; Yao X; Chan CB; Yim SY; Ye K; Warren ST; Bassell GJ
    J Neurosci; 2010 Aug; 30(32):10624-38. PubMed ID: 20702695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice.
    Han K; Chen H; Gennarino VA; Richman R; Lu HC; Zoghbi HY
    Hum Mol Genet; 2015 Apr; 24(7):1813-23. PubMed ID: 25432536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A metabolomic and systems biology perspective on the brain of the fragile X syndrome mouse model.
    Davidovic L; Navratil V; Bonaccorso CM; Catania MV; Bardoni B; Dumas ME
    Genome Res; 2011 Dec; 21(12):2190-202. PubMed ID: 21900387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic deletion of regulator of G-protein signaling 4 (RGS4) rescues a subset of fragile X related phenotypes in the FMR1 knockout mouse.
    Pacey LK; Doss L; Cifelli C; van der Kooy D; Heximer SP; Hampson DR
    Mol Cell Neurosci; 2011 Mar; 46(3):563-72. PubMed ID: 21215802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome.
    Mines MA; Jope RS
    Front Mol Neurosci; 2011; 4():35. PubMed ID: 22053151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.